PL1601361T3 - Pirydylosulfonamido-pirymidyny do leczenia nefropatii cukrzycowej - Google Patents

Pirydylosulfonamido-pirymidyny do leczenia nefropatii cukrzycowej

Info

Publication number
PL1601361T3
PL1601361T3 PL04716605T PL04716605T PL1601361T3 PL 1601361 T3 PL1601361 T3 PL 1601361T3 PL 04716605 T PL04716605 T PL 04716605T PL 04716605 T PL04716605 T PL 04716605T PL 1601361 T3 PL1601361 T3 PL 1601361T3
Authority
PL
Poland
Prior art keywords
diabetic nephropathy
pyridylsulfonamido
pyrimidines
treating diabetic
zero
Prior art date
Application number
PL04716605T
Other languages
English (en)
Inventor
Jessica Mann
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of PL1601361T3 publication Critical patent/PL1601361T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
PL04716605T 2003-03-06 2004-03-03 Pirydylosulfonamido-pirymidyny do leczenia nefropatii cukrzycowej PL1601361T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03100549A EP1454625A1 (en) 2003-03-06 2003-03-06 Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
EP04716605A EP1601361B1 (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
PCT/EP2004/050242 WO2004078104A2 (en) 2003-03-06 2004-03-03 Pyridylsulfonamido pyrimidines for treating diabetic nephropathy

Publications (1)

Publication Number Publication Date
PL1601361T3 true PL1601361T3 (pl) 2008-10-31

Family

ID=32799012

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04716605T PL1601361T3 (pl) 2003-03-06 2004-03-03 Pirydylosulfonamido-pirymidyny do leczenia nefropatii cukrzycowej

Country Status (27)

Country Link
US (2) US20060094731A1 (pl)
EP (2) EP1454625A1 (pl)
JP (1) JP4737686B2 (pl)
KR (1) KR101099189B1 (pl)
CN (1) CN100453081C (pl)
AT (1) ATE395063T1 (pl)
AU (2) AU2004216858B2 (pl)
BR (1) BRPI0408082A (pl)
CA (1) CA2517930C (pl)
CY (1) CY1108241T1 (pl)
DE (1) DE602004013734D1 (pl)
DK (1) DK1601361T3 (pl)
EC (1) ECSP056060A (pl)
ES (1) ES2305737T3 (pl)
HK (1) HK1083761A1 (pl)
HR (1) HRP20050860A2 (pl)
IL (1) IL170626A (pl)
MX (1) MXPA05009478A (pl)
NO (1) NO20054148L (pl)
NZ (1) NZ542155A (pl)
PL (1) PL1601361T3 (pl)
PT (1) PT1601361E (pl)
RS (1) RS20050683A (pl)
SI (1) SI1601361T1 (pl)
UA (1) UA82087C2 (pl)
WO (1) WO2004078104A2 (pl)
ZA (1) ZA200507122B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1595880A1 (en) * 2004-05-13 2005-11-16 Speedel Pharma AG Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
EP1924325A2 (en) * 2005-09-12 2008-05-28 Speedel Pharma AG Pyridylsulfonamidyl-pyrimidines for the prevention of blood vessel graft failure
ES2712086T3 (es) 2010-06-17 2019-05-09 Nitto Denko Corp Agente para tratar la fibrosis renal
CN109260164A (zh) * 2018-10-07 2019-01-25 威海贯标信息科技有限公司 一种阿伏生坦片剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76542A (en) * 1994-03-17 1997-09-29 Ciba Geigy Ag Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
DE69626986T2 (de) * 1995-08-02 2004-02-05 Smithkline Beecham Corp. Endothelinrezeptorantagonist
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
WO2001081335A1 (en) * 2000-04-20 2001-11-01 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity

Also Published As

Publication number Publication date
ECSP056060A (es) 2006-01-27
CY1108241T1 (el) 2013-09-04
AU2004216858A1 (en) 2004-09-16
MXPA05009478A (es) 2005-10-18
AU2004216858B2 (en) 2009-07-16
JP4737686B2 (ja) 2011-08-03
AU2009225323A1 (en) 2009-11-05
ZA200507122B (en) 2006-05-31
ES2305737T3 (es) 2008-11-01
EP1454625A1 (en) 2004-09-08
HK1083761A1 (en) 2006-07-14
HRP20050860A2 (en) 2005-10-31
ATE395063T1 (de) 2008-05-15
CA2517930A1 (en) 2004-09-16
DK1601361T3 (da) 2008-08-25
EP1601361A2 (en) 2005-12-07
NZ542155A (en) 2008-09-26
US20090005404A1 (en) 2009-01-01
CA2517930C (en) 2011-04-26
DE602004013734D1 (de) 2008-06-26
BRPI0408082A (pt) 2006-02-14
AU2009225323B2 (en) 2011-11-24
WO2004078104A3 (en) 2004-10-28
CN100453081C (zh) 2009-01-21
KR20050106083A (ko) 2005-11-08
IL170626A (en) 2010-05-31
EP1601361B1 (en) 2008-05-14
CN1756552A (zh) 2006-04-05
UA82087C2 (uk) 2008-03-11
PT1601361E (pt) 2008-07-29
JP2006519817A (ja) 2006-08-31
US20060094731A1 (en) 2006-05-04
SI1601361T1 (sl) 2008-10-31
KR101099189B1 (ko) 2011-12-27
RS20050683A (en) 2007-11-15
WO2004078104A2 (en) 2004-09-16
NO20054148L (no) 2005-09-06

Similar Documents

Publication Publication Date Title
NO20052796L (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
WO2008079339A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
DK1855677T3 (da) 3,11 B-CIS-dihydrotetrabanezin til behandling af skizofreni og andre psykoser
TW200505919A (en) DPP-IV inhibitors
GB0226930D0 (en) Chemical compounds
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
NO20051103L (no) Indol-3-karboksamider som Glukokinase-(GK)-Aktivatorer
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
DK1487444T3 (da) Anvendelse af pyridylamider som angiogeneseinhibitorer
DE602004018630D1 (en) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
ATE519762T1 (de) Benzazepinverbindungen mit affinität für den dopamin-d3-rezeptor und deren verwendung
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
HK1083761A1 (en) Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
TW200609228A (en) Substituted n-acyl-2-aminothiazoles
DE60204611D1 (de) Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
ZA200800999B (en) Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
DK1499312T3 (da) Anvendelse af hydroxypyridonderivater til sårheling
ATE338046T1 (de) 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität
DK1409490T3 (da) 2-(Aminomethyl)tetrahydro-9-oxa-1,3-diazacyclopenta[a]-naphthalenylderivater med antipsykotisk virkning
TW200519071A (en) 3-aryl-2-cyano-3-hydroxy-acrylic acid derivatives
ATE527267T1 (de) 1-ä2',3'-didesoxy-3'-c(hydroxymethyl)-b-d-eryth o-pentofuranosylü cytosinderivate als hiv- inhibitoren
TH79975A (th) ยาเพื่อการรักษาหรือการป้องกันโรคภาวะพังผืด
MX2007010218A (es) Compuestos de acido piridil acetico.